Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen which mediates its effects by binding to tyrosine kinase receptors. We have characterized the VEGF-activated intracellular signal transduction pathway in bovine aortic endothelial cells and correlated this to its mitogenic effects. VEGF induced concentration- and time-dependent increases in protein kinase C (PKC) activation with a maximum of 2.2-fold above the basal level at 5 x 10(-10) M within 10 min as measured both by in situ and translocation assays. Immunoblotting analysis of PKC isoforms in cytosolic and membrane fractions indicated that after VEGF stimulation the content of Ca(2+)-sensitive PKC isoforms (alpha and betaII) was increased in the membrane fractions, whereas no changes were observed for PKC isoforms delta and epsilon. The stimulation of PKC activity by VEGF was preceded by the activation of phospholipase Cgamma (PLCgamma). This was demonstrated by parallel increases in PLCgamma tyrosine phosphorylation, [3H]inositol phosphate production, and [3H]arachidonic acid-labeled diacylglycerol formation in bovine aortic endothelial cells. In addition, VEGF increased phosphatidylinositol 3-kinase activity 2.1-fold which was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, without decreasing the VEGF-induced increase in PKC activity or endothelial cell growth. Interestingly, genistein, a tyrosine kinase inhibitor, and GFX or H-7, PKC inhibitors, abolished both VEGF-induced PKC activation and endothelial cell proliferation. VEGF's mitogenic effect was inhibited by a PKC isoform beta-selective inhibitor, LY333531, in a concentration-dependent manner. In contrast, antisense PKC-alpha oligonucleotides enhanced VEGF-stimulated cell growth with a simultaneous decrease of 70% in PKC-alpha protein content. Thus, VEGF appears to mediate its mitogenic effects partly through the activation of the PLCgamma and PKC pathway, involving predominately PKC-beta isoform activation in endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, within the TME, PKC beta, another PKC isoform, is a well‐documented effector of the VEGF signaling that promotes angiogenesis and is required for invasiveness in certain tumors, such as pancreatic tumors [122, 123, 124].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 2×
“and assayed by the method of Bradford (19).”
MethodInfluentialA RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“The cells were scraped and total lipids were extracted with chloroform according to the methods of Bligh and Dyer (22).”
MethodVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“VEGF was independently isolated as both an endothelial cell growth factor (1) and as a vasopermeability factor (3).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472 · cited 4×
“In contrast, PKC isoforms e and d, which lack Ca(21) binding sites, are only responsive to DAG and did not translocate adequately for our antibodies to detect (25).”
BackgroundMethodInfluentialAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793 · cited 2×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
BackgroundSelf-citationGenistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724 · cited 1×
“The addition of genistein (40 mm), a tyrosine kinase inhibitor (27), significantly reduced the VEGF-induced tyrosine phosphorylation of PLCg.”
BackgroundOncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694 · cited 2×
“Since PI 3-kinase has been shown to be associated with several different tyrosine kinase receptors (29), and VEGF has been reported to increase PI 3-kinase tyrosine phosphorylation (12, 13), we determined whether PI 3-kinase activity could also be activated by VEGF.”
BackgroundThe bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275 · cited 1×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
Background
Cited by
Items 301–400 of 615
Specifying protein kinase C functions in melanoma
Denning, M. F. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01015.x · Cited by 40
“Thus, Enzastaurin may inhibit tumor growth in part by targeting endothelial cells, which express PKCb (Xia et al., 1996).”
BackgroundWatari, K., Shibata, T., Fujita, H., Shinoda, A., Murakami, Y., Abe, H., Kawahara, A., Ito, H., Akiba, J., Yoshida, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0829-0 · Cited by 39
Jesmin, S., Hattori, Y., Togashi, H., Ueno, K., Yoshioka, M., & Sakuma, I. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-7635-3 · Cited by 39
Vascular Endothelial Growth Factor: How It Transmits Its Signal
Zachary, I. C. (1998) · Nephron Experimental Nephrology · doi:10.1159/000020560 · Cited by 39
“Studies of several receptor PTKs have established that specific phosphorylated tyrosine residues serve as binding sites for the src homology (SH)-2 domains of specific intracellular signalling molecules including phosphatidylinositol 3'-kinase (PI3 kinase), phospholipase C-? (PLC-?), p120 guanosine triphosphatase acti…”
BackgroundSLEVIN, M. A., Kumar, S., He, X. T., & Gaffney, J. J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990730)82:3<412::aid-ijc15>3.0.co;2-j · Cited by 39
“PKC activity was determined in total cell lysates as described by Xia et al. (1996).”
MethodMicrocirculatory Exchange Function
Durán, W. N., Sánchez, F. A., & Breslin, J. W. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374530-9.00004-8 · Cited by 38
Svensson, K., Zeidman, R., Trollér, U., Schultz, A., & Larsson, C. U. (2000) · PubMed · Cited by 38
Kou, B., Ni, J., Vatish, M., & Singer, D. R. J. (2008) · Microcirculation · doi:10.1080/10739680701651495 · Cited by 38
“The cell proliferation in the presence of XO was further decreased by pretreatment with the PI3-K/Akt inhibitor LY294002 or Wortmannin for two hours (P 0.05 vs.”
BackgroundInfluentialPocock, T., & Bates, D. O. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00479.x · Cited by 38
“PLC is known to generate IP3 and DAG in response to VEGF in cultured endothelial cells (Xia et al. 1996).”
BackgroundInfluentialKawano, Y., Rincón, J., Soler, A., Ryder, J. W., Nolte, L. A., Zierath, J. R., & Wallberg‐Henriksson, H. (1999) · Diabetologia · doi:10.1007/s001250051273 · Cited by 38
“To determine whether PKC mediates glucose transport, we pre-incubated soleus muscle in the presence of high concentrations of glucose and either H-7, a broad base cell permeable serine-threonine kinase inhibitor known to inhibit PKC [44,45] or GF109203X, a highly selective cell-permeable PKC inhibitor [46,47].”
BackgroundVascular effects of environmental oestrogens: implications for reproductive and vascular health
Dubey, R. K. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.4.351 · Cited by 38
Pomero, F., Allione, A., Beltramo, E., Buttiglieri, S., Dalu, F. A., Ponte, E., Lacaria, A., & Porta, M. (2003) · Diabetologia · doi:10.1007/s00125-003-1044-5 · Cited by 38
“PKC-β2, in particular, mediates the angiogenic and permeability-enhancing effects of vascular endothelial growth factor-vascular permeability factor (VEGF-VPF), involved in sight-threatening diabetic retinopathy [8].”
BackgroundKruger, E. A., Blagosklonny, M. V., Dixon, S. C., & Figg, W. D. (1998) · Invasion and Metastasis · doi:10.1159/000024514 · Cited by 36
The role of VEGF in Cancer angiogenesis and tumorigenesis: Insights for anti-VEGF therapy
Shi, Z., Kuai, M., Li, B., Akowuah, C. F., Wang, Z., Pan, Y., Tang, M., Yang, X., & Lü, P. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156908 · Cited by 37
Devika, N. T., & Ali, B. M. J. (2013) · Molecular BioSystems · doi:10.1039/c3mb70258h · Cited by 37
Yadav, U. C. S., Srivastava, S. K., & Ramana, K. V. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.04.017 · Cited by 37
“Once active, VEGF binds to a receptor and initiates a signaling cascade that, in turn, activates the transcription of several genes involved in cell growth and differentiation, which leads to new vessel formation (Guo et al., 1995; Xia et al., 1996; Larrivée, & Karsan, 2000; Gliki, Wheeler-Jones, & Zachary, 2002).”
BackgroundEvans, I. M., Kennedy, S. A., Paliashvili, K., Santra, T., Yamaji, M., Lovering, R. C., Britton, G., Frankel, P., Kölch, W., & Zachary, I. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.064428 · Cited by 37
The evolution of cancer research and drug discovery at Lilly Research Laboratories
Pearce, H. L., & Miller, M. A. (2005) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2005.02.017 · Cited by 37
Kelly, D. J., Buck, D., Cox, A. J., Zhang, Y., & Gilbert, R. E. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00397.2006 · Cited by 37
“Its beneficial effects in diabetic eye disease are thought to relate, at least in part, to its ability to reduce the actions of vascular endothelial growth factor (VEGF) (30), a pro-angiogenic and permeability-enhancing cytokine that is overexpressed in both human (1) and experimental diabetic retinopathy (10).”
BackgroundBansode, R. R., Leung, T., Randolph, P. D., Williams, L. L., & Ahmedna, M. (2012) · Food Science & Nutrition · doi:10.1002/fsn3.13 · Cited by 36
“VEGF can activate several protein kinase C (PKC) isoforms, including a, b1, and b2, and d isoforms (Xia et al. 1996; Aiello et al. 1997).”
BackgroundKoyama, S., Takagi, H., Otani, A., Suzuma, K., Nishimura, K., & Honda, Y. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702564 · Cited by 36
“VEGF appears to exert its mitogenic and vasopermeable e ects partly through activation of the PLCg and PKC-dependent pathways in vascular endothelial cells (Aiello et al., 1997, Xia et al., 1996).”
BackgroundMethodSelf-citationNakamura, S., Chikaraishi, Y., Tsuruma, K., Shimazawa, M., & Hara, H. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.09.022 · Cited by 36
Sheetz, M. J., Aiello, L. P., Shahri, N., Davis, M. D., Kles, K. A., & Danis, R. P. (2011) · Retina · doi:10.1097/iae.0b013e3181fe545f · Cited by 35
Self-citationGlycine inhibits angiogenesis in colorectal cancer: role of endothelial cells
Bruns, H., Kazanavičius, D., Schultze, D. P., Al‐Saeedi, M., Yamanaka, K., Strupas, K., & Schemmer, P. (2016) · Amino Acids · doi:10.1007/s00726-016-2278-0 · Cited by 35
“…migration of endothelial cells is dependent upon increased intracellular Ca2+, activation of GlyR leads to increased intracellular Cl− concentration, which further prevents intracellular Ca2+ influx and may suppress VEGF-induced angiogenesis (Xia et al. 1996; Betz and Becker 1988; Bormann 1988).”
BackgroundPharmacologic therapies for diabetic retinopathy and diabetic macular edema.
Rechtman, E., Harris, A., Garzozi, H. J., & Ciulla, T. A. (2007) · PubMed Central · Cited by 34
Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis.
Affara, N. I., & Robertson, F. M. (2004) · PubMed · Cited by 34
Hanauske, A.-R., Oberschmidt, O., Hanauske-Abel, H. M., Lahn, M. M. F., & Eismann, U. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9038-7 · Cited by 34
“It has been suggested that PKC-β is the predominat mediator of VEGF-induced cell proliferation [7, 8].”
BackgroundSurgical and Other Treatments of Diabetic Macular Edema: An Update
Christoforidis, J. B., & Amico, D. J. D. (2004) · International Ophthalmology Clinics · doi:10.1097/00004397-200404410-00015 · Cited by 34
Wang, J., Morita, I., Onodera, M., & Murota, S. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10059 · Cited by 34
“The tyrosine-phosphorylated receptors also stimulate cellular responses involving PLC-g (Takahashi and Shibuya, 1997), PKC (Xia et al., 1996), phosphatidylinostial 3-kinase (PI3 kinase) (Wu and Patterson, 1999), and MAPK activation (D'Angelo et al., 1995).”
BackgroundOdia, Y., Sul, J., Shih, J. H., Kreisl, T. N., Butman, J. A., IWAMOTO, F. M., & Fine, H. A. (2016) · CNS Oncology · doi:10.2217/cns-2015-0010 · Cited by 33
Zhang, H., Gao, Y., Zhang, J., Wang, K., Jin, T., Wang, H., Ruan, K., Wu, F. H., & Xu, Z. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112773 · Cited by 33
Therapeutic Applications of PI3K Inhibitors in Cardiovascular Diseases
Ghigo, A., Morello, F., Perino, A., & Hirsch, E. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.11 · Cited by 33
PENTRAXIN 3 AND OTHER INFLAMMATORY FACTORS IN CENTRAL RETINAL VEIN OCCLUSION AND MACULAR EDEMA
Noma, H., Mimura, T., Masahara, H., & Shimada, K. (2013) · Retina · doi:10.1097/iae.0b013e3182993d74 · Cited by 32
Small molecular weight G-protein, H-Ras, and retinal endothelial cell apoptosis in diabetes
Kowluru, R. A., Kowluru, A., & Kanwar, M. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9299-z · Cited by 32
Emerging drugs for diabetic retinopathy
Mohamed, Q. A., & Wong, T. Y. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584035 · Cited by 32
“VEGF binding to either receptor type triggers phosphoinositol hydrolysis, and activation of some PKC isoforms and associated effects [94] .”
BackgroundKhurana, R., Shafi, S., Martin, J. F., & Zachary, I. C. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000128127.57688.e0 · Cited by 32
Zhao, S., Huang, L., Wu, J., Zhang, Y., Pan, D., & Liu, X. (2009) · PubMed Central · Cited by 31
Protein Kinase C Beta in the Tumor Microenvironment Promotes Mammary Tumorigenesis
Wallace, J. A., Pitarresi, J. R., Sharma, N., Palettas, M. S., Cuitiño, M. C., Sizemore, S. T., Yu, L., Sanderlin, A. G., Rosol, T. J., Mehta, K. D., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00087 · Cited by 31
Li, S., Phong, M., Lahn, M. M. F., Brail, L. H., Sutton, S. E., Lin, B. K., Thornton, D., & Liao, B. (2007) · Biology Direct · doi:10.1186/1745-6150-2-8 · Cited by 31
“Protein kinase C-beta (PKC-β) is a regulator of the vascular endothelial growth factor (VEGF) signal cascade and angiogenesis [3-7].”
BackgroundGlycine as a Therapeutic Immuno‐Nutrient for Alcoholic Liver Disease
Yamashina, S., Ikejima, K., Enomoto, N., Takei, Y., & Sato, N. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000189281.82523.6c · Cited by 31
Control of angiogenesis dictated by picomolar superoxide levels
Bir, S. C., Shen, X., Kavanagh, T. J., Kevil, C. G., & Pattillo, C. B. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.015 · Cited by 30
“VEGF induces various endothelial cell (EC) responses including EC remodeling through VEGFR-1/Flt-1 and VEGFR-2/Flk-1/KDR that are necessary for vascular development during ischemic angiogenesis [34, 35].”
BackgroundPathophysiology of Diabetic Retinopathy
Stewart, M. W. (2010) · Springer eBooks · doi:10.1007/978-0-387-85900-2_1 · Cited by 30
Yoo, M. H., Hyun, H. J., Koh, J., & Yoon, Y. H. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0376 · Cited by 30
Kuroyanagi, J., Shimada, Y., Zhang, B., Ariyoshi, M., Umemoto, N., Nishimura, Y., & Tanaka, T. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.07.033 · Cited by 30
“PKC isozymes, in particular PKCb, a binding partner of ZMYND8, are important mediators of VEGF signalling, and their inhibition leads to decreased endothelial cell proliferation and a reduction in neovascularization of malignant tumours [29,30].”
BackgroundThe Epidemiology of Complications
Bloomgarden, Z. T. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.924 · Cited by 30
“PKC activation appears to be the final pathway mediating both an increase in retinal vascular permeability, causing macular edema, and an increase in retinal neovascularization, in the development of diabetic retinopathy (17).”
BackgroundSafety and pharmacokinetics of multiple dose myo-inositol in preterm infants
Phelps, D. L., Ward, R. M., Williams, R. L., Nolen, T. L., Watterberg, K. L., Oh, W., Goedecke, M., Ehrenkranz, R. A., Fennell, T. R., Poindexter, B. B., et al. (2016) · Pediatric Research · doi:10.1038/pr.2016.97 · Cited by 29
“Therefore, inositol or its derivatives may be rate limiting in the roles of VEGF, IGF-1, or other factors critical to retinal vascular development which normally occurs in-utero from 14 to 36 weeks gestation.”
BackgroundNitric oxide signaling during myocardial angiogenesis
Kondo, T., Kobayashi, K., & Murohara, T. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000044371.06317.0a · Cited by 29
“More recently it has been assumed that Src, a cytoplasmic protein tyrosin kinase, becomes activated in ECs following binding to an activated VEGF receptors.”
BackgroundInfluentialComplications of type 1 diabetes: new molecular findings
Stirban, A. O., Rosen, P., & Tschoepe, D. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20057 · Cited by 30
Recent Medical Management of Glioblastoma
Johnson, D. R., & Chang, S. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3146-6_3 · Cited by 28
“Increased PKC activity stimulates angiogenesis through interplay with the VEGF system.(68) PKC also activates the phosphoinositide 3-kinase (PI3K) second messenger cascade which plays an important role in cellular survival and regulation of apoptosis.”
BackgroundReview of therapeutic advances in diabetic retinopathy
Chen, C. G., & Shah, C. P. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810396750 · Cited by 28
O papel da proteína quinase C no desenvolvimento das complicações vasculares do diabetes mellitus
Schaan, B. D. (2003) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302003000600006 · Cited by 28
The Protein Kinase C Inhibitor: Ruboxistaurin
Deissler, H. L., & Lang, G. E. (2015) · Developments in ophthalmology · doi:10.1159/000431204 · Cited by 28
Teicher, B. A., Álvarez, E., Mendelsohn, L. G., Ara, G., Menon, K., & Ways, D. K. (1999) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(98)00026-0 · Cited by 28
VEGF-receptor inhibitors for anti-angiogenesis.
Shibuya, M. (2003) · Folia Pharmacologica Japonica · doi:10.1254/fpj.122.498 · Cited by 28
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Klasa, R. J., List, A. F., & Cheson, B. D. (2001) · Hematology · doi:10.1182/asheducation-2001.1.443 · Cited by 28
Sulpice, E., Contrerès, J.-O., Lacour, J., Bryckaert, M., & Tobelem, G. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04263.x · Cited by 29
Morgillo, F., Martinelli, E., Troiani, T., Laus, G., Pepe, S., Gridelli, C., & Ciardiello, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0547 · Cited by 26
“In this respect, the phosphatidylinositol 3-kinase (PI3K)/ Akt pathway stimulates cell cycle progression, suppresses apoptosis, and is frequently activated by different mechanisms in a variety of human cancers (11, 12).”
Backgroundde Jonge, H. J. M., Weidenaar, A. C., ter Elst, A., Boezen, H. M., Scherpen, F. J. G., Steege, J. C. A. B.-T., Kaspers, G. J. L., Goemans, B. F., Creutzig, U., Zimmermann, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1821 · Cited by 26
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
Gelardi, T., Caputo, R., Damiano, V., Daniele, G., Pepe, S., Ciardiello, F., Lahn, M., Bianco, R., & Tortora, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604493 · Cited by 26
“The protein kinase C (PKC), particularly the PKCb isoform, is involved in VEGFR signal transduction (Xia et al, 1996) and can lead to the overproduction of VEGF, as well as to the inhibition of apoptotic cell death (Yoshiji et al, 1999; Tsai et al, 2003).”
BackgroundGlycine as a potent anti‐angiogenic nutrient for tumor growth
Yamashina, S., Ikejima, K., Rusyn, I., & Sato, N. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04655.x · Cited by 26
Strategies for the synthesis of N-(azacycloalkyl)bisindolylmaleimides: selective inhibitors of PKCβ
Faul, M. M., Grutsch, J. L., Kobierski, M. E., Kopach, M. E., Krumrich, C. A., Staszak, M. A., Udodong, U. E., Vicenzi, J. T., & Sullivan, K. A. M. (2003) · Tetrahedron · doi:10.1016/s0040-4020(03)00973-6 · Cited by 26
Aiello, L. P., Cahill, M. T., & Cavallerano, J. D. (2004) · Eye · doi:10.1038/sj.eye.6700585 · Cited by 26
Self-citationWilkinson‐Berka, J. L., Kelly, D. J., & Gilbert, R. E. (2001) · Journal of Vascular Research · doi:10.1159/000051088 · Cited by 26
“Deciphering the specific functions of PKC in vivo has been limited by the toxicity of general PKC inhibitors such as staurosporine, GF 109203X and H-7. More recently, a non-toxic, orally active compound (LY333531) that specifically inhibits the PKC s isoform has been developed. Recent studies have suggested that both…”
BackgroundCell cycle molecules and diseases of the cardiovascular system
Stefka, B. P. (2000) · Frontiers in bioscience · doi:10.2741/petkova · Cited by 26
“For example, restoration of functional p16 in human gliomas led suppression of tumor vascularization through downregulation of vascular endothelial growth factor (VEGF) expression (56).”
BackgroundInfluentialAlshammari, R. A., Aleanizy, F. S., Aldarwesh, A., Alqahtani, F. Y., Mahdi, W. A., AlQuadeib, B. T., Alqahtani, Q. H., Haq, N., Shakeel, F., Abdelhady, H. G., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071444 · Cited by 25
Retinal Function and Morphology in Rabbit After Intravitreal Injection of VEGF Inhibitors
Myers, A. C., Adrian, M. L., Bruun, A., Ghosh, F. K., Andréasson, S., & Ponjavic, V. (2012) · Current Eye Research · doi:10.3109/02713683.2011.611609 · Cited by 25
Changing Times for the Management of Diabetic Retinopathy
Fong, D. S. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00389-2 · Cited by 25
Redox regulation of cardiac protein kinase C.
Korichneva, I. L. (2005) · PubMed Central · Cited by 24
Murata, M., KADOR, P., & Sato, S. (2000) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2000.16.383 · Cited by 23
Abrams, S. T., Brown, B. R. B., Zuzel, M., & Slupsky, J. R. (2010) · Blood · doi:10.1182/blood-2009-06-229872 · Cited by 22
Targeting Protein Kinase C Downstream of Growth Factor and Adhesion Signalling
Dowling, C. M., & Kiely, P. D. W. (2015) · Cancers · doi:10.3390/cancers7030836 · Cited by 22
“The isozyme plays a role in mediating VEGF signalling and its inhibition in this pathway results in decreased endothelial cell proliferation and reduction of neovascularization in malignant tumours [133,134].”
BackgroundGökmen‐Polar, Y., Mehta, R. J., Tüzmen, Ş., Mousses, S., Thorat, M. A., Sanders, K. L., Turbin, D. A., Leung, S. C. Y., Huntsman, D. D., Sledge, G. W., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0733-2 · Cited by 22
“In endothelial cells, VEGF mediates its mitogenic effects partly through the activation of the phospholipase C-c (PLCc) and PKC pathways, PKCbII being the predominant PKC isozyme in these cells [20].”
BackgroundResultAndrés, V. (1998) · Frontiers in bioscience · doi:10.2741/a240 · Cited by 22
Current and future pharmacological intervention for diabetic retinopathy
Comer, G. M., & Ciulla, T. A. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.441 · Cited by 22
“PKC-β helps regulate endothelial cell permeability [85,86], blood flow [87] and angiogenesis as a signalling component for VEGF [88,89].”
BackgroundDeissler, H. L., Deißler, H., & Lang, G. E. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3917 · Cited by 22
Higuchi, A., Yamada, H., Yamada, E., Jo, N., & Matsumura, M. (2011) · PubMed Central · doi:10.6084/m9.figshare.73865 · Cited by 21
Vascular Complications in Diabetes: Mechanisms and the Influence of Antioxidants
Rosen, P., Tritschler, H., & Packer, L. (2001) · CRC Press eBooks · doi:10.1201/9780203904046.ch25 · Cited by 21
DeBosch, B. J., Deo, B. K., & Kumagai, A. K. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00848.x · Cited by 21
“The concentrations selected for each inhibitor were based on prior experiments (Sone et al. 2000; DeBosch et al. 2001), as well as published reports (Vlahos et al. 1994; Alessi et al. 1995; Tsakiridis et al. 1995; Xia et al. 1996).”
Ling, S., Little, P. J., Williams, M. R. I., Dai, A., Hashimura, K., Liu, J., Komesaroff, P. A., & Sudhir, K. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00111.2001 · Cited by 21
Eye vessels saved by rescuing their pericyte partners
Antonetti, D. A. (2009) · Nature Medicine · doi:10.1038/nm1109-1248 · Cited by 20
Kou, B., Vatish, M., & Singer, D. R. J. (2007) · Vascular Pharmacology · doi:10.1016/j.vph.2007.06.011 · Cited by 20
“VEGF activates receptor tyrosine kinases leading to the activation of various signal transducers including PI-3K (Guo et al., 1995; Xia et al., 1996).”
BackgroundTreatment of Diabetic Retinopathy with Protein Kinase C Subtype &Bgr; Inhibitor
Lang, G. E. (2007) · KARGER eBooks · doi:10.1159/000098506 · Cited by 20
Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
Shimokawa, T., Seike, M., Soeno, C., Uesaka, H., Miyanaga, A., Mizutani, H., Kitamura, K., Minegishi, Y., Noro, R., Okano, T., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.7 · Cited by 19
“JAK1 STAT3 P=0.0001 *** 1.05 P=0.01511.5 1.00 0.95 0.90 0.85 **11.0 10.5 10.0 9.5 VEGFR2 VEGFR3 ResistantSensitive 0.80 ResistantSensitive 9.0 P=0.03 P=0.003 P=0.04 ** 1.5 1.0 0.5 P=0.05 ** 1.2 1.0 0.6 0.4 0.8 ResistantSensitive 0 ResistantSensitive 0.2 0 hsa-miR-21TMEM49/MIRN21 2.01.10 ***** 1.5 1.0 0.5 1.00 0.90 Res…”
BackgroundInfluentialMoser, K. V., & Humpel, C. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2004.12.005 · Cited by 19
Granulocyte colony-stimulating factor-induced activation of protein kinase-C in myeloid cells
Deshpande, R. V., Peterson, R. H. F., & Moore, M. A. S. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970901)66:3<286::aid-jcb2>3.0.co;2-l · Cited by 19
Signal transduction in angiogenesis
Zachary, I. C. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7311-3_18 · Cited by 19
VEGF Attenuates Hyperoxic Injury through Decreased Apoptosis in Explanted Rat Embryonic Lung
Esquibies, A. E., Bazzy‐Asaad, A., Ghassemi, F., Nishio, H., Karihaloo, A. K., & Cantley, L. G. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e31815b4857 · Cited by 18
“Based on its known regulation by oxygen concentration and ability to stimulate lung development (24), we examined the possibility that suppression of VEGF expression was contributing to the growth inhibition seen under hyperoxic culture conditions.”
BackgroundDiabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy
Broadgate, S., Kiire, C. A., Halford, S., & Chong, V. N. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13678 · Cited by 18
“The binding activates a signalling cascade that in turn, activates the transcription of several genes involved in cell growth and differentiation, which leads to new vessel formation (Xia et al. 1996; Larrivee & Karsan 2000; Gao et al. 2001; Gliki et al. 2002; Yadav et al. 2012).”
BackgroundKumar, R., Mani, A. M., Singh, N. K., & Rao, G. N. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2522-0 · Cited by 18
Bräutigam, K., Bauerschlag, D., Weigel, M. T., Biernath-Wüpping, J., Bauknecht, T., Arnold, N., Maass, N., & Meinhold-Heerlein, I. M. (2009) · Translational Oncology · doi:10.1593/tlo.09121 · Cited by 18
“Several reports have shown that activation of PKC is required for tumor-induced angiogenesis [7,8].”
BackgroundYamaguchi, H., Igarashi, M., Hirata, A., Susa, S., Ohnuma, H., Tominaga, M., Daimon, M., & Kato, T. (2001) · Endocrine Journal · doi:10.1507/endocrj.48.433 · Cited by 18
Vascular endothelial growth factor increases the intracellular magnesium
Hong, B.-Z., Kang, H., So, J.-N., Kim, H., Park, S., Kim, S., Kim, K.-R., & Kwak, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.125 · Cited by 17
Key Signaling Pathways and Targets in Lung Cancer Therapy
Choong, N. W., Salgia, R., & Vokes, E. E. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.s.002 · Cited by 17
Emerging drugs for age-related macular degeneration
Augustin, A. J., & Offermann, I. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.4.725 · Cited by 17
Regulatory Effects of Soluble Growth Factors on Choriocapillaris Endothelial Growth and Survival
Liu, X., Ye, X., Yanoff, M., & Li, W. (1998) · Ophthalmic Research · doi:10.1159/000055489 · Cited by 17
Rikitake, Y., Kawashima, S., Takahashi, T., Ueyama, T., Ishido, S., Inoue, N., Hirata, K., & Yokoyama, M. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.1.h266 · Cited by 17
Hepatocyte Growth Factor Inhibits VEGF-Forkhead–Dependent Gene Expression in Endothelial Cells
Abid, M. R., Nadeau, R. J., Spokes, K., Minami, T., Li, D., Shih, S., & Aird, W. C. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.175109 · Cited by 16
Zhang, K., Ferreyra, H. A., Grob, S., Bedell, M., & Zhang, J. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00046-1 · Cited by 16
Induction of VE-cadherin in rat placental trophoblasts by VEGF through a NO-dependent pathway
Chang, C., Chang, T.-Y., Yu, C.-H., & Tsai, M.-L. (2004) · Placenta · doi:10.1016/j.placenta.2004.06.002 · Cited by 16
“In the progression phase, VEGF increases endothelial proliferation [26,27].”
BackgroundNovel approaches to the treatment of progressive renal disease
Gilbert, R. E., Kelly, D. J., & Atkins, R. C. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00023-6 · Cited by 16
Metadata
- Authors
- Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L.
- Affiliations
- Joslin Diabetes Center (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2018-2026
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507645
- OpenAlex
- W2075553837
- Cited by
- 566
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 14 · 2013: 21 · 2012: 19
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (5r01dk036433-10, 5r29ey010827-04, 5r01ey005110-18, EY05110)
- National Eye Institute (EY10827, EY05110)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK36433)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- vascular endothelial growth factor, protein kinase C, PKC isoforms, PKC beta, endothelial cell proliferation, signal transduction, phospholipase C-gamma, phosphatidylinositol 3-kinase, diacylglycerol, ruboxistaurin, genistein, wortmannin, bovine aortic endothelial cells
- MeSH terms
- Animals, Cattle, Cell Division, Diglycerides, Endothelium, Vascular, Enzyme Activation, Inositol Phosphates, Isoenzymes, Lymphokines, Type C Phospholipases, Protein Kinase C, Signal Transduction, Endothelial Growth Factors, DNA, Antisense, Phosphotransferases (Alcohol Group Acceptor), Phosphotyrosine, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Phospholipase C gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.